期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 31, 期 15, 页码 1815-1824出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2012.46.5948
关键词
-
类别
资金
- Dana-Farber Cancer Institute
- National Institutes of Health [R33 CA155554]
Ongoing global genome characterization efforts are revolutionizing our knowledge of cancer genomics and tumor biology. In parallel, information gleaned from these studies on driver cancer gene alterations-mutations, copy number alterations, translocations, and/or chromosomal rearrangements-can be leveraged, in principle, to develop a cohesive framework for individualized cancer treatment. These possibilities have been enabled, to a large degree, by revolutionary advances in genomic technologies that facilitate systematic profiling for hallmark cancer genetic alterations at increasingly fine resolutions. Ongoing innovations in existing genomics technologies, as well as the many emerging technologies, will likely continue to advance translational cancer genomics and precision cancer medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据